Skip to main content
Premium Trial:

Request an Annual Quote

Orchid s Revenues and Loss Up in Q1; Company to Genotype Irish Sheep

NEW YORK, May 6 (GenomeWeb News) - Orchid BioSciences reported increased revenues and widening losses for the first quarter of 2004 today.

 

Revenues for the quarter totaled $13.5 million, up from $12.7 million during the first quarter of 2003.

 

R&D costs declined to $0.5 million, from $1.1 million for the year-ago period.

 

The company's net loss, which includes losses from Orchid's diagnostics unit, which it sold to Tepnel Life Sciences in January, was $8.1 million, or $.41 per share, up from $5 million, or $.45 per share, during the same quarter last year.

 

As of March 31, Orchid had $31.7 million in cash and cash equivalents and $1 million in restricted cash. This includes $28.1 million the company raised in an equity financing in February and by selling its diagnostics unit.

 

Separately, Orchid said today that its Cellmark unit will provide genotyping services for the National Genotyping Programme of the government of Ireland to help breed sheep with reduced susceptibility to scrapie.

 

Cellmark, which is part of Orchid BioSciences Europe, will make its genotyping services available to the 45,000 flock owners of Ireland.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.